Suchergebnisse - "Heymach, John V"

PubPharm (652)

21

Methods of treating cancer with kinase inhibitors

enthalten in: Europäisches Patentamt | 2024

von ROBICHOT JACQUES P | HEYMACH JOHN V | SCHICK SIMON

22

Perioperative Durvalumab for Resectable Non-Small-Cell Lung Cancer. Reply

enthalten in: The New England journal of medicine | 2024

von Heymach, J. | Harpole, D. | Reck, M.

CommentOn: N Engl J Med. 2023 Nov 2;389(18):1672-1684. - PMID 37870974

23

METHODS AND SYSTEMS FOR DIAGNOSIS, CLASSIFICATION, AND TREATMENT OF SMALL CELL LUNG CANCER AND OTHER HIGH-GRADE NEUROENDOCRINE CARCINOMAS

enthalten in: Europäisches Patentamt | 2024

von HEYMACH JOHN V | HEEKE SIMON | BYERS LAUREN A | +1

24

Effects of KRAS Genetic Interactions on Outcomes in Cancers of the Lung, Pancreas, and Colorectum

enthalten in: Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology | 2024

von Grabski, I. | Heymach, J. | Kehl, K. | +7

25

METHODS AND COMPOSITIONS FOR TREATING NON-SMALL CELL LUNG CANCER

enthalten in: Europäisches Patentamt | 2024

von HEYMACH JOHN V | NILSSON MONIQUE

26

METHODS AND COMPOSITIONS FOR TREATING NON-SMALL CELL LUNG CANCER

enthalten in: Europäisches Patentamt | 2024

von HEYMACH JOHN V | NILSSON MONIQUE

27

HER4 and EGFR Activate Cell Signaling in NRG1 Fusion-Driven Cancers : Implications for HER2-HER3-specific Versus Pan-HER Targeting Strategies

enthalten in: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer | 2024

von Udagawa, H. | Nilsson, M. | Robichaux, J. | +15

28

YAP1 status defines two intrinsic subtypes of LCNEC with distinct molecular features and therapeutic vulnerabilities

enthalten in: bioRxiv.org | 2023

von Stewart, C. | Diao, L. | Xi, Y. | +25

29

METHODS AND SYSTEMS FOR CLASSIFICATION AND TREATMENT OF SMALL CELL LUNG CANCER

enthalten in: Europäisches Patentamt | 2023

von PARK ELIZABETH M | BYERS LAUREN A | GAY CARL M | +1

30

Clinical and molecular characterization of long-term survivors with extensive-stage small cell lung cancer treated with first-line atezolizumab plus carboplatin and etoposide

enthalten in: Lung cancer (Amsterdam, Netherlands) | 2023

von Liu, S. | Mok, T. | Nabet, B. | +18